Pfizer Ophthalmics Carl Camras Translational Research Award recent recipients

The Pfizer Ophthalmics Carl Camras Translational Research Awards recognize a young researcher who is 45 years of age or less at the time of nomination. This person will have exhibited excellence in research and their fundamental scientific discoveries, concepts and novel technologies. Their discovery or observation must have led to, or have the promise of leading to, clinical application.

2014 Camras Award recipients

Apte Photo

Rajendra Apte, MD, PhD (IM)
Washington University School of Medicine

Apte has established himself as a leading clinician-scientist in the area of ocular inflammation and neovascularization in the eye. He was the first to demonstrate that macrophage migration inhibitory factor (MIF) is found in the aqueous humor and profoundly suppresses natural killer (NK) cell activity in the eye and protects the retina from NK cell-mediated injury. His findings spawned a series of translational studies, which led to an age-related macular degeneration (AMD) drug development initiative and biomarker development for dry eye disease and AMD.

Hafezi photo Farhad Hafezi, MD, PhD (CO)
Geneva University Hospitals,
and University of Southern California, Los Angeles

Hafezi’s translational research is exemplified through his contribution to developing and bringing to market the CXL method. He was one of the core team of innovators who transitioned this method from basic/pre-clinical studies to later arresting corneal degeneration caused by keratoconus in patients. A full-time clinician and surgeon, he also founded a company in Switzerland that will significantly expand the market of the CXL treatment modality. His scientific work has been cited more than 2,800 times.

Scholl photo Hendrik P.N. Scholl, MD, MA (RE)
Johns Hopkins University School of Medicine

Scholl’s work in the area of genetically determined panretinal and macular dystrophies and age-related macular degeneration (AMD) has substantially contributed to the understanding of the pathophysiology of blinding eye diseases. His research contributions represent an extraordinary advancement in the field and Scholl is internationally recognized for his innovative and pioneering work in this area. He presents a unique combination as being one of the few retinal dystrophy experts in the world who is also an accomplished vitreo-retinal surgeon.